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ABSTRACT 
Diabetic retinopathy (DR) is a disease of Dristipatala. Raktapitta, Dosha Avarana and Dhatukshya are the 
main etiological factors involved. Madhumeha is vatika type of Prameha and all the three Dosha and 
Saptadhatu except Asthidahtu gets vitiated. Mainly Rakta, Mamsa and Meda dhatu affected by both 
etiopathological mechanisms of Avarana and Dhatukshya. Agnimandya and Ama formation are initiating 
factors of the main disease Madhumeha and all these leads to complications similar to Raktapitta due to 
Rasayani daurvalya. Ojas kshaya is another etiological factor in Madhumeha. In Pranavritta vyana Vyanavayu 
gets obstructed by Pranavayu and leads to Indriyasunyata. Raktavritta vata too have a role in development of 
DR Pathology. Timir is described under Vataja nanattmaja vyadhi by Charaka. Vagbhata and Yogratnakara 
advised Basti chikitsa in Timir vyadhi. By considering the above facts Panchatikta Panchaprasrittika Basti 
was considered for this trial to reduce pathology of Sira abhisyandam and vasculopathy in diabetic 
retinopathy cases. Tilatailadi Yoga was considered to reduce hemorrhagic effects in retina and as Nasya is 
the shortest and effective route for CNS drug delivery for vision improvement, Tilatailadi Nasya was 
considered for this study. Amrutadi Guggulu was considered for this study, as it has anti-inflammatory, 
antioxidant, hypolipidemic and above all Srotosodhaka properties, which is particularly indicated for Timir 
vyadhi. Thus in present study an attempt has been made to prevent and check the progression of different 
stages of non proliferative stages of diabetic retinopathy (NPDR). Mixed results were obtained with 
statistically significant improvement in visual acuity, fundus signs and laboratory parameters. 
KEYWORDS: Diabetic Retinopathy, NPDR, Panchatikta Basti, Nasya Karma, Amrutadi Guggulu, Patalagata 
Timir.
INTRODUCTION 
Diabetes mellitus is a life style disorder which 
originates due to improper dietary habits and sedentary 
life style and is one of the most prevalent metabolic 
diseases of present times. Diabetes affects almost all 
aspects of intermediary metabolism and is also associated 
with accelerated ageing of the cardiovascular system. 
Hence diabetes is best defined as a metabolic cum vascular 
syndrome of multiple etiologies characterized by chronic 
hyperglycemia with disturbances of carbohydrate, fat and 
protein metabolism resulting from defects in insulin 
secretion, insulin action or both, leading to changes in both 
small blood vessels (microangiopathy) and large blood 
vessels (macroangiopathy) and which is often associated 
with long term damage, leading to malfunction and failure 
of various organs like eyes, kidneys, heart, nerves and 
blood vessels.[1] 
Diabetic retinopathy is a chronic progressive, 
potentially sight-threatening disease of the retinal 
microvasculature associated with prolonged 
hyperglycemia and other conditions linked to diabetes 
mellitus are hypertension, hyperlipidemia and proteinuria 
etc.[2] Almost all the patients with Type I diabetes develop 
retinopathy in about 15 years. Diabetics have a 20-25 
times greater risk of blindness as compared to the normal 
population.[3] Prevalence of DR in Wisconsin 
Epidemiological Study of Diabetic Retinopathy (WESDR) 
was 50.1% and 54.2% in the diabetes control and 
complications trial (DCCT) in IDDM and 35-39% in United 
Kingdom Prospective Diabetes Study (UKPDS) in NIDDM. 
In two studies from South India, the prevalence rates of DR 
in NIDDM patients were 34.1% and 37%. In the Chennai 
Urban Rural Epidemiology Study (CURES), we evaluated 
urban sample of diabetic patients and estimated the 
overall prevalence of DR as 17.6%. The Diabetic 
Retinopathy Study (DRS) and the Early Treatment Diabetic 
Retinopathy Study (ETDRS) have shown that early 
treatment can reduce the risk of relentless vision loss by 
57%. [4] 
 On viewing the above burden of DR in society an 
effective and comprehensive approach is necessary to 
address this global problem. Though modern medicine has 
solutions in early PDR and PDR stages, like 
Photocoagulation, intravitreal steroids and Anti VEGF 
injections but these too have their own complications and 
side effects in varying degree. Thus in this study an 
attempt has been made to explore the possibilities to 
prevent and check the progression of diabetic retinopathy 
with Ayurveda interventions. Strategies aimed at 
therapeutic interventions in diabetic retinopathy were 
based on the understanding of etiological and pathological 
mechanisms behind its development and progression in 
both modern medicine and Ayurveda. Hence an attempt 
was made to study the efficacy of Panchatikta Niruha 
(Panchatikta Panchaprasritika) Basti, Tilatailadi Nasya and 
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Amrutadi Guggulu in the management of different stages of 
Diabetic Retinopathy. 
MATERIAL AND METHODS 
Aims & Objectives 
1. To evaluate the efficacy of Pancha Tikta Pancha 
Prasrutik Basti, Tilatiladi Nasya and Amrutadi Guggulu 
in early diabetic retinopathy cases. 
2. To reduce the risk of vision loss or slow the 
progression of Diabetic retinopathy in patients with 
mild to severe non proliferative or early proliferative 
diabetic retinoipathy. 
3. To find out a probable correlation and 
etiopathogenesis of Diabetic retinopathy in Ayurveda. 
Sources of Data – Patients of either sex diagnosed with 
mild to severe NPDR were selected for this study from OPD 
and IPD of Shalakya Department of National Institute of 
Ayurveda Hospital, Jaipur, Rajasthan, India. The ethical 
committee (IEC, NIA, Jaipur) clearance number of the 
clinical study is F 10 (5)/EC/2014/7224 dated 7/11/2014.  
Criteria for selection of patients 
 Patients attending the O.P.D. and I.P.D. of N.I.A. 
were screened having the signs and symptoms of diabetic 
retinopathy. The diagnosis was done on the basis of careful 
history taking and clinical examination. 
Inclusion criteria 
1. Diagnosed cases of Diabetes both Type I and Type II. 
2. Mild to severe non proliferative Diabetic retinopathy 
with or without Macular edema. 
3. Visual acuity more than 6/60 
4. Age between 20 -70 yrs. 
Exclusion criteria 
1. Visual acuity- less than 6/60 
2. Uncontrolled Hypertensive patients with systolic 
BP>170 and diastolic BP>110 mm Hg. 
3. Pregnant diabetic patients.  
4. Diabetic patients with other cardiovascular problems 
like CAD, Post MI, post CABG cases. 
Clinical study was accomplished in three phases: 
Diagnostic Phase, Interventional Phase and Assessment 
Phase. 
Diagnostic criteria 
 Selected patient were subjected to a complete 
examination; findings were recorded in the specially 
designed case proforma and fundus drawing charts for 
diabetic retinopathy examination as per Ayurveda and 
Modern parameters. 
The examinations which were carried out are: 
1. Best corrected visual acuity (BCVA) using snellen’s 
chart (for distant vision) and Jauguar’s chart (for near 
vision) with Log MAR visual acuity notations. 
2. Slit lamp examination for any gross pathology in 
anterior segment. 
3. Ocular pressure was examined by both non contact 
tonometry (NCT) and Schiotz tonometry method. 
4. Fundus was examined by Direct Ophthalmoscope and 
Indirect slit lamp bio microscope with +90 D lens after 
complete pupil dilation with a short acting mydriatic 
Tropicacyl plus eye drops. (Combination of 
Phenylepinephrine and Tropicamide). Findings were 
recorded in fundus drawing charts for before and after 
treatment.  
Lab investigations 
Eight parameters were assessed before and after 
treatment i.e. CBC, ESR, FBS, PPBS, Lipid profile, Blood 
urea, Serum creatinine and Urine albumin.  
Design of the study: This study is designed with an open 
label pre and post study evaluation method. A comparative 
study between two groups was also done.  
Interventions 
 A total of 30 patients diagnosed with diabetic 
retinopathy from mild to severe NPDR stages were 
selected and randomly divided into two groups A & B, each 
group having 15 patients, by using random number table. 
Each group was subjected to the treatment in the following 
methods. 
Group A: Patients were treated with Panchatikta 
Panchaprasrittika Basti (PPB) along with Amrutadi 
Guggulu (AG) tablet orally. After sadyasnehana and 
swedana, kostha sodhana was adopted depending on the 
kostha and prakritti of the patient. Trikatu churna was 
used for deepna pachana and Go ghrita was used for 
sadyasnehana. Triphala churna was given for kostha 
sodhana. After kostha suddhi the patient were given PPB (8 
No of Basti) on every alternate day for 16 days and 2 
tablets of Amrutadi Guggulu (500mg each) was also given 
orally along with this treatment for 30 days.  
Group B: After Kostha suddhi selected patients of Diabetic 
retinopathy were administered Tilatailadi Marsha Nasya 
(8 drops each nostril) daily for 7 days and orally 2 tablets 
of Amrutadi guggulu (500mg each) twice daily with water 
after food for 30 days. Purvakarma with Dasamoola taila 
Mukha abhyanga followed by Mridu swedana was done. 
And after mucous removal the patients were given saline 
water Kaval (saindhva lavana mixed in warm water) as 
Paschat Karma.  
Follow up – Follow up was done after one month of 
completion of treatment.  
Methods of preparation of Trial Drugs 
 Tilatailadi Nasya[5] contains Tilataila, 
Bibhitakataila, Bhringaraja and Vijayasara (Asana) and 
was prepared by the Tailapaka vidhi.  
 Amrutadi Guggulu[6] a compound drug contains 17 
drugs namely Triphala, Guduchi, Vasa, Patola, 
Raktachandana, Musta, Katuki, Kutaja, Chirayata, Chitraka, 
Duralabha, Yava, Gambhari, Sunthi and Sudha Guggulu. All 
the trial drugs were prepared in GMP certified Pharmacy 
of National Institute of Ayurveda, Jaipur.  
 Pancha Tikta Pancha Prashritika Basti[7] contain 
following ingredients in different proportion according to 
the quotation given in Charak Samhita, as shown below. 
 It was prepared by adding four Prashrit 
(4×80=320 ml) decoction of Patol, Nimba, Bhunimba, 
Rasna, Saptaparna and one Prashrit (80 ml) Go-ghrita with 
Sarshapa Kalka (Paste of Brassica comprestris)  
1. Kwath (Decoction of Patol, Nimba, Bhunimba, Rashna, 
Saptaparna) 320 ml. 
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2. Kalka (for the present study 10g of sarshapa kalka was 
taken, as 40g of sarshapa kalka practically causes adverse 
effects like burning micturation and reduced Basti 
retention time ) [8] 
3. Ghee as Sneha -80 ml 
4. Bee honey 80 ml 
5. Saindhava (Rock salt) 5 g 
Preparation of the Basti Dravya: All the ingredients were 
are taken in the required quantity. Initially Madhu (bee 
honey) and rock salt, were triturated until sound 
disappears, then Sneha, Kalka, Kvatha and Avapa Dravya 
were added sequentially keeping triturating in progress 
until it becomes a homogeneous mixture.[9] Then the 
mixture was heated indirectly in hot water bath to make 
Sukhoshna i.e. nearer to the normal body temperature. 
Basti was administered as per classical methods of Niruha 
Basti procedure and Ahara Vihara followed accordingly. 
ASSESSMENT CRITERIA 
 The effect of treatment was assessed on the basis 
of both subjective and objective criteria according to a self 
designed scoring system. Scoring methods for objective 
parameters are mentioned in Table No.1. 
Table 1: Objective assessment criteria 
 
Microaneurysms 
0- Absent : No microaneurysms 
1- Mild : < 1/12th of Fundus area 
2- Moderate : 1/12th to < 3/12th of fundus area 
3- Severe : 3/12th or more of fundus area 
 
Intra Retinal 
Haemorrhage 
 
0- Absent : No haemorrages 
1- Mild : < 1/12th of fundus area 
2- Modearate : 1/12th to < 3/12th of fundus area 
3- Severe : 3/12th or more of fundus area 
 
Exudates 
 
 
0- Absents : No Exudates 
1- Mild : < 1/12th of fundus area 
2- Moderate : 1/12th to < 3/12th of fundus area 
3- Severe : 3/12th or more of fundus area. 
Subjective assessment criteria 
1. Diminished Vision: 
Grade 0- No diminished vision 
Grade 1- Diminished vision but without imitating activities 
Grade 2- Sometimes difficulty in performing routine work 
Grade 3- Unable to do things independently 
2. Frequent changes in Presbyopic number 
Grade 0- No frequent change in Presbyopic number 
Grade 1- Change in Presbyopic number in 3-4 months 
Grade 2- Change in Presbyopic number in every 2 months 
Grade 3- Change in Presbyopic number in every 15-30 
days 
3. Floaters 
Grade 0- No perception of floaters 
Grade 1- Occasionally interfering with routine work. 
Grade 2- Regularly interfering with routine work. 
Grade 3- Can’t perform routine work. 
4. Flashes of light 
Grade 0- No perception of flashes of light. 
Grade 1- Occasionally interfering with routine work. 
Grade 2- Regular interfering with routine work. 
Grade 3- Unable to perform routine work. 
5. Dark Adaptation 
Grade 0- Adaptation to darkness within few seconds. 
Grade 1- Slow dark adaptation within 10- 20 seconds 
Grade 2- Slower dark adaptation within 20-30 seconds. 
Grade 3- Slowest dark adaptation beyond 30 seconds. 
 
 
Visual acuity assessment 
Visual acuity assessment was done with Log MAR visual 
acuity notations with Snellen’s visual acuity chart. Visual 
acuity notations are depicted in Table No.2. 
Table 2: Visual Acuity Notations 
Visual Acuity Notations 
Snellens 
(6/6) 
LogMAR 
(0) 
Snellens 
(6/6) 
LogMAR 
(0) 
6/3 -0.3 6/48 0.9 
6/4 -0.2 6/60 1.0 
6/5 -0.1 5/60 1.1 
6/6 0 4/60 1.2 
6/7.5 0.1 3/60 1.3 
6/9 0.2 2.5/60 1.4 
6/12 0.3 2/60 1.5 
6/15 0.4 1.5/60 1.6 
6/18 0.5 1.25/60 1.7 
6/24 0.6 1/60 1.8 
 0.7 0.75/60 1.9 
6/36 0.8 0.5/60 2.0 
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STATISTICAL ANALYSIS 
 The scoring of criteria of assessment was analysed 
statistically in terms of mean values of B.T. (Before 
Treatment), A.T (After treatment), S.D (Standard 
Deviation), and S.E (Standard Error). Various observations 
were made and results obtained were computed 
statistically using Student t test, Wilcoxon matched pairs 
signed ranks test and Mann Whitney test on Graph Pad 
Instat 3 software. The results obtained were considered 
extremely significant for p value <0.001, very significant 
for <0.01, significant for p value <0.05 and non significant 
for p value >0.05.  
OBSERVATIONS 
On Age: Maximum patients (53.33%) were of age group 
between 61-70 years. On Gender: The incidence of sex in 
the groups shows female preponderance (60%) as 
compared to males (40%). 
On Education: Maximum patients of the study (43.33%) 
were educated up to primary standards only. This shows 
their unawareness towards their health status and regular 
checkups. On Onset of DR: In the study, all (100%) patients 
had gradual onset of ocular complaints. On duration of DM: 
Maximum numbers of patients (40%) were having history 
of Diabetes up to 5 years. 30% reported duration of 6-10 
years and 23.33% of patients DM for 11-15 years. This 
shows minimum of 5 years of duration of DM is required 
for development of DR sing and symptoms. On family 
history of DM/DR: Positive family history of DM was found 
in 60% of the patients. Rest (40%) reported absence of any 
family history. On Bowel/Kostha: 60% of patients were 
having Krura kostha, 26.66% having Madhyama kostha and 
rest 13.33% had Mridu kostha. This data indirectly 
indicates towards Vatavriddhi in maximum of patients. 
Again this data matched with the quote from Sushruta 
“madhumehinam durvirechyaha”. 
RESULTS 
  On comparison both the groups showed 
insignificant results in all the objective parameters except 
soft exudates which was significant (p=0.0358) at p<0.05 
and Group A showed significant than Group B as mean 
difference Group A> Group B. On microaneurysm, flame 
shape hemorrhages, dot/blot hemorrahages, and intra 
retinal microvascular abnormalities (IRMA) were none of 
the groups showed significant results. But individually 
Group A showed significant results on Hard exudates 
(p=0.0156) at p<0.05. [Table No.3, 4] 
Table 3: Effect of Therapy on Objective parameters in Group A (Wilcoxon matched pairs signed ranks test) 
Parameters Mean D % of 
Relief 
SD ± SE± W P Remarks 
BT AT 
Microaneurysm  1.467 1.300 0.1667 11.36 0.3790 0.06920 15.000 0.0625 NS 
Flame shape. H 0.8667 0.7333  0.1333 15.38 0.3457 0.06312 10.000 0.1250 NS 
Dot/ blot. H 1.033 0.9000 0.1333  12.90 0.3457 0.06312 10.000 0.1250 NS 
Hard exudate 1.333 1.100 0.2333 17.50 0.4302 0.07854 28.000 0.0156 S 
Soft Exudate 0.2667 0.2333 0.03333 12.49 0.7649 0.1396 6.000 0.8311 NS 
IRMA 0.5667 0.4333 0.1333 23.52 0.3457 0.06312 10.000 0.1250 NS 
Table 4: Effect of Therapy on Objective parameters in Group B (Wilcoxon matched pairs signed ranks test) 
Parameters Mean D % of 
Relief 
SD ± SE± W P Remarks 
BT AT 
Microaneurysm  1.267 1.133 0.1333 10.52 0.3457 0.06312 10.000 0.1250 NS 
Flame shape. H 0.4333  0.3000 0.1333 30.76 0.3457 0.06312 10.000 0.1250 NS 
Dot/ blot. H 0.4000 0.2667 0.1333 33.32 0.3457 0.06312 10.000 0.1250 NS 
Hard exudate 0.5667 0.5333 0.03333 5.88 0.1826 0.03333 1.000 > 0.9999 NS 
Soft Exudate 0.2667 0.1333 0.1333 49.98 0.5074 0.09264 3.000 0.5000 NS 
IRMA 0.3000 0.1667  0.1333 44.43 0.3457 0.06312 10.000 0.1250 NS 
On comparison both the group showed same results in all the subjective symptoms and are not significant. But individually 
the effects of therapy in Group A on diminish of vision and delayed dark adaptation showed significant results than Group 
B. On perception of flashes of light the Group A only showed significant results. None of the groups showed significant 
results on visual perception of floaters. [Table No.5, 6] 
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Table 5: Effect of Therapy on Subjective parameters in Group A (Wilcoxon matched pairs signed ranks test) 
Parameters Mean D % of 
Relief 
SD ± SE± W P Remarks 
BT AT 
Diminish of Vision 1.767 1.233  0.5333 30.18 0.5074 0.09264 136.00 < 0.0001 ES 
Frequent change in 
Presbyopic glasses 
0.6000 0.3333 0.2667 44.45 0.4498 0.08212 36.000 0.0078 VS 
Perception of flashes 
of light 
0.8000  0.6000 0.2000 25.00 0.4068 0.07428 21.000 0.0313 S 
Floaters 0.8333  0.6897 0.1724 20.68 0.3844 0.07139 15.000 0.0625 NS 
Delayed dark 
Adaptation 
1.367  0.7333 0.6333 46.32 0.5561 0.1015 171.00 < 0.0001 ES 
Table 6: Effect of Therapy on Subjective parameters in Group B (Wilcoxon matched pairs signed ranks test) 
Parameters Mean D % of 
Relief 
SD ± SE± W P Remarks 
BT AT 
Diminish of Vision 1.333 0.6667 0.6667 50.01 0.4795 0.08754 210.00 < 0.0001 ES 
Frequent change in 
Presbyopic glasses 
0.5333 0.4333  0.1000 18.75 0.3051 0.05571 6.000 0.2500 NS 
Perception of 
flashes of light 
0.2069 0.06667  0.1379 28.11 0.3509 0.06517 10.000 0.1250 NS 
Floaters 0.4333  0.3000 0.1333 30.76 0.3457 0.06312 10.000 0.1250 NS 
Delayed dark 
Adaptation 
1.067 0.7667 0.3000 28.11 0.4661 0.08510 45.000 0.0039 VS 
 On comparison of both groups on best corrected visual acuity (BCVA) it was found statistically significant (p=0.0119) at 
p<0.05. As the mean score of Group A is 0.2387 > 0.1207 of Group B, So effect of therapy on visual acuity in group A is 
better than Group B by 49.43%.But individually both groups showed extremely significant results on visual acuity with 
31.27% relief in Group A and 35.5% relief in Group B. [Table.No.7, 8] 
Table 7: Effect of Therapy on BCVA (Log MAR) (Student Paired- t test) Group A 
BCVA (LogMAR) Mean D % of 
Relief 
Paired “t” test P Remarks 
BT AT SD ± SE± t 
RE 0.7733  0.4893 0.2840 36.72 0.1973 0.05094 5.575 < 0.0001 ES 
LE 0.7533 0.5600  0.1933 25.66 0.2120 0.05474 3.532 0.0033 VS 
BOTH (30 Eyes) 0.7633 0.5247  0.2387 31.27 0.2064 0.03769 6.332 < 0.0001 ES 
Table 8: Effect of Therapy on BCVA (Log MAR) (Student Paired- t test) Group B 
BCVA 
(LogMAR) 
Mean D % of 
Relief 
Paired “t” test P Remarks 
BT AT SD ± SE± t 
RE 0.3667 0.2360  0.1307 35.64 0.1504 0.03882 3.366 0.0046 VS 
LE 0.3133 0.2027 0.1107 35.33 0.1309 0.03380 3.274 0.0055 VS 
BOTH (30 Eyes) 0.3400 0.2193 0.1207 35.50 0.1389 0.02536 4.759 < 0.0001 ES 
 On comparison of both the groups showed same 
results on all the parameters of laboratory investigations 
except urea, creatinine and urine albumin, which was 
significant for urea and creatinine and very significant for 
urine albumin. Thus on the basis of mean difference Group 
A showed better results than Group B on urea, creatinine 
and urine albumin. On ESR Group A showed better result 
with 23.49% relief, than Group B (3.86%). On FBS none of 
the groups showed significant results. On PPBS Group A 
showed better results than Group B. On Total cholesterol 
and Triglyceride level of lipid profile study, Group B 
showed better results than Group A. 
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DISCUSSION 
 Diabetic retinopathy basically Dristipatalagata 
roga and is mainly attributed to Sira srotas abhisyandam 
and Raktavaha sroto dusti due to a variety of 
Achakshyushya ahara and Vihara karanas especially in 
Prameha patients.[10] Etiological factors of Madhumeha, 
Raktaja vyadhi and endogenic eye diseases are almost 
similar and are mainly Achakshyushya factors which vitiate 
Pitta and Rakta. This explains the logical approach 
towards the development of microvascular complication in 
diabetic retinopathy cases and manifested as symptoms of 
Urdhwaga raktapitta. The whole pathology of Diabetic 
retinopathy starts with microangiopathy, which is clearly 
stated in Ayurveda as Sroto dusti of Raktavaha srotos, 
manifested as Attipravriti, Sanga and Granthi as 
haemorrhages, exudates and venous beading in diabetic 
retinopathy respectively.  
 In this study individually the effects of therapy in 
Group A on diminish of vision (DOV) and delayed dark 
adaptation (DA) showed significant results than Group B 
and this may be attributed to improvement in lens changes 
and retinal/ macular edema. The reduction in blood sugar 
and retinal edema by oral drug Amrutadi Guggulu (AG) and 
Panchatikta Pancha Prasritika Basti (PPB) in group A is 
potentially due to reduction in morbid Raktapitta dosha 
and Sothahara, Rasayana properties of the drugs in PPB 
and AG. Both the treatments might have helped in 
increasing the nutritional status of sensory cells of the 
retina by improving the quality of blood and reducing the 
retinal edema and thereby the quality of Chakshyu 
vaisheshika Alochaka pitta improved. Improvement in lipid 
profile, serum albumin and ESR in group A might be 
responsible for improvement in hard exudates, which 
again attributes to PPB and AG treatment in Group A. Anti-
inflammatory and hypolipidemic properties of drugs in 
PPB and AG led to the improvements in Hard Exudates in 
diabetic retinopathy cases. Soft exudates (cotton-wool 
spots) are fluffy white lesions that occur in the posterior 
pole as a result of axonal degeneration of the nerve fiber 
layer and develop in areas of arteriolar occlusion. 
Vatahara and Rasyana, properties of Rasna in PPB were 
responsible for improvement in soft exudates in Group A 
patients. On fundus signs there were not much 
comparative significant effect. But individually Group A 
showed better results particularly in hard exudates and 
soft exudates/cotton wool spots. The better results in 
Group A reflected the therapeutic effectiveness of Basti as 
main line of treatment for Timir chikitsa. Contents of PPB 
and AG are having Raktaprasadana, Chaksyusya, Rasayana 
properties with anti-inflammatory, lipid lowering activities 
and healing properties (Ropanakarma) on blood 
capillaries.  
 Visual acuity was improved about 30% in both the 
groups with better improvement in Group A. This shows 
the importance of Basti chikitsa in Patalagata timir. The 
drugs contents of Basti were having anti-inflammatory, 
Chakshyusya, Rasayana and Raktaprasadana properties. As 
visual acuity is particularly the function of macula, 
improvement in BCVA shows that therapy in Group A was 
more effective in reducing macular edema. Lipid profile, 
blood sugar and urine albumin were improved 
significantly in Group A. Reduction in proteinuria, blood 
sugar and lipid profile might have impact in improvement 
of macular edema due to both PPB and AG treatment in 
Group A. The treatments in Group A were more effective 
than Group B on urine albumin reduction. As renal 
function and urine albumin has direct role in pathogenesis 
of DR and macular/retinal edema formation, significant 
reduction in urine albumin in Group A has definite role in 
improvement in visual acuity. More over the presence of 
gross proteinuria at base line is associated with 95% 
increased risk of developing diabetic macular edema in 
WESDR study. Blood sugar reduction Group B is more 
effective than Group A. This may be attributed to neuro 
endocrine stimulation due to Nasya therapy with 
Tilatailadi Yog which contains Bibhitaka, Vijayasara and 
Bhringaraja. However in group A blood sugar reduction 
was not significant, this is because more number of 
patients in this group were in severe category with 
uncontrolled blood sugar and Tikta kasaya properties of 
drugs might have increases the Ruksha guna of Vata 
leading to more Dhatukshaya.  
CONCLUSION 
 Panchatikta Pancha Prashritika Basti by virtue of 
its Tikta Kasaya Rasa pradhan drugs, Chaksyusya, Ropana, 
Rasayana, Vatasamaka, Madhumehanasak and anti-
inflammatory properties were effective in promoting 
Srotosodhana of Raktavaha Srotas, thus promoted 
improvement in vision. All the drugs in PPB were having 
antioxidant properties, this might have led to 
detoxification and reduction in Ama formation, and this 
way helped in Raktavaha srotosodhana. Reduction in hard 
exudates and soft exudates in patients of DR draws 
conclusion that Basti treatment can be an effective therapy 
in diabetic retinopathy cases. Bringaraj and Bibhitak in 
Tilatailadi Yoga are having Raktapittashamaka and 
Chakshyusya properties. Nasya therapy has its direct action 
on neuro endocrine stimulation and gets absorbed in 
Sirasrotas via cavernous sinus. Vision improvement in 
Group B proves that Tilatailadi Nasya can be included in 
treatment protocol of DR. Amrutadi Guggulu can be an 
effective drug for diabetic retinopathy treatment. 
Reduction in lipid profile, renal function tests and urine 
albumin in both the groups showed that, this drug could 
have helped in purifying the micro channels of body and 
retinal micro vessels as well. Vision improvement in both 
the groups showed that the drugs and procedures were 
effective in reduction of macular edema. But duration of 
therapy should be prolonged to get desired result. Above 
all Quality of Vision was improved in both the groups. Non 
significant results on clinical findings in Group B indicates 
that comprehensive management including Sodhana, 
shaman and Rasayana chikitsa are required to address the 
multiple etiological factors in DR cases. 
All the procedures of this study, combined in one 
group can be studied with a control group may give new 
insight in DR management through Ayurveda. Different 
types of Basti can be planned in different stages of DR 
based on Brimhana Shodhana and Langhana Sodhana. FFA 
(Fundus Flourescein Angiography) and OCT (Optical 
Coherence Tomography) should be included in study for 
assessment of Retinal and Macular edema. Drug delivery to 
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posterior segment can be studied by plasma concentration 
analysis and by matching biomarkers of drugs after Basti 
procedure. As Diabetic retinopathy is a diseases of 
Dritipatala and Patalas are based on Dhatus and all the 
Patalas are gets affected in DR pathology, thus for 
enhancing the drug effect duration of therapy should be 
increased. Since the sample size and duration of therapy 
was small, so data in many subjective and objective 
findings are not much conclusive. 
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